ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
퍼제타(퍼투주맙) 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 2029년까지 연평균 성장률(CAGR) 16%로 성장해 $1,932.7억 달러에 달할 것으로 전망됩니다. 예측 기간 동안의 성장은 유방암 발병률의 증가, 혈액 악성 종양에 대한 ADC에 대한 관심 증가, 암 발병률의 증가, 암 발병률 및 충족되지 않은 의료 요구의 증가, 암 면역 요법에 대한 제약 R&D의 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 종양학에 바이오시밀러의 채택, 바이오시밀러 및 제네릭 의약품의 개발, 의약품 제형 혁신, 암 면역 요법 연구의 발전, 복합 요법의 부상이 있습니다.
유방암 발병률의 증가는 퍼제타(퍼투주맙) 시장의 성장을 촉진할 것으로 예상됩니다. 유방암은 유방 조직에 악성 세포가 발생하며, 종종 유관이나 소엽에서 시작되는 질병입니다. 유방암 발병률의 증가는 비만율 증가, 앉아있는 생활 습관 등 생활 습관의 변화와 함께 광범위한 검진 프로그램을 통한 조기 발견의 개선과 같은 요인에 기인합니다. 퍼제타(퍼투주맙)는 HER2 수용체를 표적화하여 HER2 양성 유방암을 치료하며, 일반적으로 트라스투주맙과 화학요법과 병용 투여되어 치료 효과를 높입니다. 예를 들어, 2023년 10월, 영국에 본사를 둔 자선 단체인 Ray of Light Wales는 영국에서 유방암 진단을 받은 후 생존하는 사람의 수가 2023년 60만 명에서 2030년에는 120만 명으로 두 배로 증가할 것으로 전망했습니다. 따라서 유방암 발병률의 증가는 페르제타 시장의 성장을 촉진하고 있습니다.
퍼제타(퍼투주맙) 시장의 주요 동향은 환자의 치료 결과 및 치료 편의성을 개선하기 위해 피하 복합 요법 등 기술적으로 진보된 솔루션의 개발에 초점을 맞추고 있습니다. 피하 복합 요법은 특정 질환을 치료하기 위해 두 가지 이상의 의약품을 단일 피하 주사로 투여하는 요법입니다. 2023년 11월, 일본에 본사를 두고 있는 제약 회사인 Chugai Pharmaceutical Co., Ltd.는 HER2 양성 유방암 및 진행성 또는 재발성 HER2 양성 대장암을 위한 피하 투여 복합 치료제인 Phesgo를 출시했습니다. 이 혁신적인 치료제는 퍼투주맙과 trastuzumab에 vorhyaluronidase alfa를 결합해 5-8분 만에 투여 가능하며, 전통적인 정맥 주입에 비해 시간을 크게 단축합니다. Phesgo는 HER2 양성 대장암에 대한 첫 번째 피하 투여 옵션으로, 치료 전달 방식에서 중요한 진전을 이룬 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 퍼제타(퍼투주맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 퍼제타(퍼투주맙) 시장 : 성장률 분석
세계의 퍼제타(퍼투주맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 퍼제타(퍼투주맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 퍼제타(퍼투주맙) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 퍼제타(퍼투주맙) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
인간 유래
동물 유래
세계의 퍼제타(퍼투주맙) 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
생물제제
세계의 퍼제타(퍼투주맙) 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
조기 유방암
전이성 유방암
세계의 퍼제타(퍼투주맙) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 퍼제타(퍼투주맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 퍼제타(퍼투주맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
퍼제타(퍼투주맙) 시장 : 경쟁 구도
퍼제타(퍼투주맙) 시장 : 기업 프로파일
Roche Holding AG
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
퍼제타(퍼투주맙) 시장(2029년) : 새로운 기회를 제공하는 국가
퍼제타(퍼투주맙) 시장(2029년) : 새로운 기회를 제공하는 부문
퍼제타(퍼투주맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Perjeta (pertuzumab) is a targeted therapy used in the treatment of specific types of breast cancer. It is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2), a protein that accelerates the growth of cancer cells in HER2-positive breast cancer.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of perjeta (pertuzumab) are human source and animal source. While Perjeta is a monoclonal antibody developed through recombinant DNA technology and produced using mammalian cell lines, animal-derived components may be used in the production process. It includes products like monoclonal antibodies and biologic drugs, with indications for conditions such as early-stage and metastatic breast cancer. Perjeta is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $1,932.7 million in 2029 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to the rising incidence of breast cancer, rising interest in ADCs for hematologic malignancies, rising incidence of cancer, rising cancer incidence and unmet medical needs, and increasing pharmaceutical R&D for cancer immunotherapy. Major trends in the forecast period include the adoption of biosimilars in oncology, the development of biosimilars and generics, innovation in drug formulations, advances in cancer immunotherapy research, and combination therapies gaining prominence.
The rising incidence of breast cancer is expected to drive the growth of the perjeta (pertuzumab) market. Breast cancer is a disease where malignant cells develop in breast tissue, often originating in the ducts or lobules. The increase in breast cancer cases is attributed to factors like lifestyle changes, such as higher obesity rates and sedentary habits, along with improvements in early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy for enhanced treatment outcomes. For example, in October 2023, the Ray of Light Wales, a UK-based charity, reported that the number of people living after a breast cancer diagnosis in the UK is projected to double from 600,000 in 2023 to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the growth of the perjeta market.
A key trend in the perjeta (pertuzumab) market is the focus on developing technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve the combination of two or more drugs in a single subcutaneous injection to treat a specific condition. In November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment combines pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing time compared to traditional intravenous infusions. Phesgo is the first subcutaneous option for HER2-positive colorectal cancer, marking a major advancement in treatment delivery.
In June 2024, Zydus Pharmaceuticals, an India-based company, partnered with Dr. Reddy's Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve the affordability, availability, and patient outcomes by leveraging their combined distribution efforts. Dr. Reddy's Laboratories, a key player in the Indian pharmaceutical sector, offers pertuzumab biosimilars, making this partnership a significant step toward increasing the accessibility of this treatment in the region.
Key player operating in the perjeta (pertuzumab) market is Roche Holding AG.
North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in perjeta (pertuzumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the perjeta (pertuzumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Perjeta (Pertuzumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on perjeta (pertuzumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for perjeta (pertuzumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The perjeta (pertuzumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Human source; Animal source
2) By Product: Monoclonal Antibody; Biologic Drug
3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Perjeta (Pertuzumab) Market Characteristics
3. Perjeta (Pertuzumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Perjeta (Pertuzumab) Market Trends And Strategies
5. Perjeta (Pertuzumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Perjeta (Pertuzumab) Growth Analysis And Strategic Analysis Framework
6.1. Global Perjeta (Pertuzumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Perjeta (Pertuzumab) Market Growth Rate Analysis
6.4. Global Perjeta (Pertuzumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Perjeta (Pertuzumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Perjeta (Pertuzumab) Total Addressable Market (TAM)
7. Global Perjeta (Pertuzumab) Market Pricing Analysis & Forecasts
8. Perjeta (Pertuzumab) Market Segmentation
8.1. Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human source
Animal source
8.2. Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody
Biologic Drug
8.3. Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Breast Cancer
Metastatic Breast Cancer
8.4. Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
9. Global Perjeta (Pertuzumab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Perjeta (Pertuzumab) Market Regional And Country Analysis
10.1. Global Perjeta (Pertuzumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Perjeta (Pertuzumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
